Precigen, Inc. (PGEN)
7.17
-0.03
(-0.42%)
USD |
NASDAQ |
Aug 24, 16:00
7.18
+0.01
(+0.14%)
After-Hours: 20:00
Precigen Enterprise Value : 2.627B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 2.627B |
| August 21, 2026 | 2.638B |
| August 20, 2026 | 2.724B |
| August 19, 2026 | 2.623B |
| August 18, 2026 | 2.477B |
| August 17, 2026 | 2.405B |
| August 14, 2026 | 2.244B |
| August 13, 2026 | 2.384B |
| August 12, 2026 | 2.512B |
| August 11, 2026 | 2.516B |
| August 10, 2026 | 2.566B |
| August 07, 2026 | 2.649B |
| August 06, 2026 | 2.534B |
| August 05, 2026 | 2.527B |
| August 04, 2026 | 2.398B |
| August 03, 2026 | 2.427B |
| July 31, 2026 | 2.305B |
| July 30, 2026 | 2.187B |
| July 29, 2026 | 2.011B |
| July 28, 2026 | 2.040B |
| July 27, 2026 | 2.001B |
| July 24, 2026 | 1.993B |
| July 23, 2026 | 2.044B |
| July 22, 2026 | 1.965B |
| July 21, 2026 | 2.026B |
| Date | Value |
|---|---|
| July 20, 2026 | 1.875B |
| July 17, 2026 | 1.832B |
| July 16, 2026 | 1.832B |
| July 15, 2026 | 1.893B |
| July 14, 2026 | 1.893B |
| July 13, 2026 | 1.911B |
| July 10, 2026 | 1.965B |
| July 09, 2026 | 2.040B |
| July 08, 2026 | 2.051B |
| July 07, 2026 | 2.033B |
| July 06, 2026 | 2.065B |
| July 02, 2026 | 2.079B |
| July 01, 2026 | 1.940B |
| June 30, 2026 | 2.101B |
| June 29, 2026 | 2.149B |
| June 26, 2026 | 2.128B |
| June 25, 2026 | 2.007B |
| June 24, 2026 | 1.964B |
| June 23, 2026 | 1.950B |
| June 22, 2026 | 1.957B |
| June 18, 2026 | 1.757B |
| June 17, 2026 | 1.725B |
| June 16, 2026 | 1.733B |
| June 15, 2026 | 1.750B |
| June 12, 2026 | 1.626B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Geron Corp. | 925.59M |
| Elicio Therapeutics, Inc. | 55.93M |
| Agenus, Inc. | 591.52M |
| Amgen, Inc. | 283.25B |
| Anika Therapeutics, Inc. | 272.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 20.07M |
| Revenue (Quarterly) | 54.98M |
| Total Expenses (Quarterly) | 34.91M |
| EPS Diluted (Quarterly) | 0.0485 |
| Gross Profit Margin (Quarterly) | 94.32% |
| Profit Margin (Quarterly) | 36.51% |
| Earnings Yield | -15.33% |
| Normalized Earnings Yield | -11.79 |